{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:54:39Z","timestamp":1770296079300,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec><jats:title>Hintergrund und Ziele<\/jats:title><jats:p>Die Behandlung schwerer dermatologischer Autoimmunerkrankungen und der toxischen epidermalen Nekrolyse (TEN) mit hoch dosierten intraven\u00f6sen Immunglobulinen (IVIg) ist ein bew\u00e4hrtes therapeutisches Verfahren in der Dermatologie. Da eine IVIg-Therapie in der Regel nur bei seltenen Erkrankungen oder bei schweren F\u00e4llen in Betracht gezogen wird, st\u00fctzt sich die Anwendung von Immunglobulinen zumeist nicht auf Daten aus randomisierten kontrollierten Studien, wie sie in der evidenzbasierten Medizin erforderlich sind. Da Indikationen f\u00fcr die Anwendung von IVIg selten sind, ist es unwahrscheinlich, dass solche Studien in absehbarer Zeit durchgef\u00fchrt werden. Da der Einsatz von IVIg als Therapie der ersten Wahl aufgrund der hohen Kosten begrenzt ist, wurden erste klinische Leitlinien f\u00fcr die Anwendung von IVIg bei dermatologischen Erkrankungen im Jahr 2008 herausgegeben und im Jahr 2011 \u00fcberarbeitet.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patienten und Methoden<\/jats:title><jats:p>Die europ\u00e4ischen Leitlinien wurden von einer Gruppe durch das EDF (\u201eEuropean Dermatology Forum\u201c) und die EADV (\u201eEuropean Academy of Dermatology and Venereology\u201c) benannter Experten erarbeitet. Die Leitlinien wurden erstellt, um die derzeit als wirksam erachteten Behandlungsindikationen zu aktualisieren und die Evidenz der f\u00fcr die Anwendung von IVIg bei dermatologischen Autoimmunerkrankungen und TEN vorliegenden Daten zusammenzufassen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ergebnisse und Schlussfolgerung<\/jats:title><jats:p>Die vorliegenden Leitlinien repr\u00e4sentieren die einvernehmliche Meinung und Definitionen von Experten zur Anwendung von IVIg, die die aktuell publizierten Daten widerspiegeln, und sollen als Entscheidungshilfe f\u00fcr den Einsatz von IVIg bei dermatologischen Erkrankungen dienen.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00105-020-04610-6","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T15:03:58Z","timestamp":1589987038000},"page":"542-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Europ\u00e4ische Leitlinien (S1) f\u00fcr die Verwendung von hoch dosierten intraven\u00f6sen Immunglobulinen in der Dermatologie","European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology"],"prefix":"10.1007","volume":"71","author":[{"given":"Eva","family":"Hadaschik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger","family":"Eming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Jolles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarolta","family":"Karpati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Steinbrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrix","family":"Volc-Platzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Enk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"4610_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab\u00a0I, Nimmerjahn\u00a0F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13:176\u2013189","journal-title":"Nat Rev Immunol"},{"key":"4610_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature10134","volume":"475","author":"RM Anthony","year":"2011","unstructured":"Anthony\u00a0RM, Kobayashi\u00a0T, Wermeling\u00a0F et\u00a0al (2011) Intravenous gammaglobulin suppresses inflammation through a\u00a0novel T(H)2 pathway. Nature 475:110\u2013113","journal-title":"Nature"},{"key":"4610_CR3","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1182\/blood-2008-02-138073","volume":"112","author":"AS De Groot","year":"2008","unstructured":"De Groot\u00a0AS, Moise\u00a0L, McMurray\u00a0JA et al (2008) Activation of natural regulatory T cells by IgG Fc-derived peptide \u201cTregitopes\u201d. Blood 112:3303\u20133311","journal-title":"Blood"},{"key":"4610_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10875-012-9752-6","volume":"33","author":"MS Maddur","year":"2013","unstructured":"Maddur\u00a0MS, Sharma\u00a0M, Hedge\u00a0P et al (2013) Inhibitory effect of IVIG on IL17-production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparation. J\u00a0Clin Immunol 33:62\u201366","journal-title":"J Clin Immunol"},{"key":"4610_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1046\/j.1610-0387.2003.02028.x","volume":"1","author":"A Enk","year":"2003","unstructured":"Enk\u00a0A, Hertl\u00a0M, Messer\u00a0G et\u00a0al (2003) The use of high dose intravenous immunoglobulins in dermatology. J\u00a0Dtsch Dermatol Ges 1:183\u2013190","journal-title":"J Dtsch Dermatol Ges"},{"key":"4610_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archderm.134.1.80","volume":"134","author":"S Jolles","year":"1998","unstructured":"Jolles\u00a0S, Hughes\u00a0J, Whittaker\u00a0S (1998) Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 134:80\u201386","journal-title":"Arch Dermatol"},{"key":"4610_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/art.20078","volume":"51","author":"J van de Vlekkert","year":"2004","unstructured":"van de Vlekkert\u00a0J, Tjin-A-Ton\u00a0ML, Hoogendijk\u00a0JE (2004) Quality of myositis case reports open to improvement. Arthritis Rheum 51:148\u2013150","journal-title":"Arthritis Rheum"},{"key":"4610_CR8","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"27","author":"MC Dalakas","year":"1993","unstructured":"Dalakas\u00a0MC, Illa\u00a0I, Dambrosia\u00a0JM et al (1993) A controlled trial of high-dose intravenous immune infusions as treatment for dermatomyositis. N\u00a0Engl J Med 27:1993\u20132000","journal-title":"N Engl J Med"},{"key":"4610_CR9","first-page":"CD003643","volume":"8","author":"PA Gordon","year":"2012","unstructured":"Gordon\u00a0PA, Winer\u00a0JB, Hoogendijk\u00a0JE et\u00a0al (2012) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 8:CD3643","journal-title":"Cochrane Database Syst Rev"},{"key":"4610_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/adc.72.1.25","volume":"72","author":"A Sansome","year":"1995","unstructured":"Sansome\u00a0A, Dubowitz\u00a0V (1995) Intravenous immunoglobulin in juvenile dermatomyositis\u2014four year review of nine cases. Arch Dis Child 72:25\u201328","journal-title":"Arch Dis Child"},{"key":"4610_CR11","doi-asserted-by":"publisher","first-page":"70S","DOI":"10.1007\/BF01540896","volume":"15","author":"MC Dalakas","year":"1995","unstructured":"Dalakas\u00a0MC (1995) Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. J\u00a0Clin Immunol 15:70S\u201375S","journal-title":"J Clin Immunol"},{"key":"4610_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","volume":"10","author":"MG Danieli","year":"2011","unstructured":"Danieli\u00a0MG, Pettinari\u00a0L, Moretti\u00a0R et\u00a0al (2011) Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a\u00a0novel application. Autoimmun Rev 10:144\u2013149","journal-title":"Autoimmun Rev"},{"key":"4610_CR13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","volume":"58","author":"DF Murrell","year":"2008","unstructured":"Murrell\u00a0DF, Dick\u00a0S, Ahmed\u00a0AR et\u00a0al (2008) Consensus statement on definitions on disease, end points and therapeutic response for pemphigus. J\u00a0Am Acad Dermatol 58:1043\u20131046","journal-title":"J Am Acad Dermatol"},{"key":"4610_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","volume":"60","author":"M Amagai","year":"2009","unstructured":"Amagai\u00a0M, Ikeda\u00a0S, Shimizu\u00a0H et al (2009) A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J\u00a0Am Acad Dermatol 60:595\u2013603","journal-title":"J Am Acad Dermatol"},{"key":"4610_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/11533290-000000000-00000","volume":"11","author":"HM G\u00fcrcan","year":"2010","unstructured":"G\u00fcrcan\u00a0HM, Jeph\u00a0S, Ahmed\u00a0AR (2010) Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering disease: a\u00a0review of the evidence for its efficacy and safety. Am J Clin Dermatol 11:315\u2013326","journal-title":"Am J Clin Dermatol"},{"key":"4610_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clim.2003.11.002","volume":"111","author":"E Letko","year":"2004","unstructured":"Letko\u00a0E, Miserocchi\u00a0E, Daoud\u00a0YJ et\u00a0al (2004) A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 111:303\u2013310","journal-title":"Clin Immunol"},{"key":"4610_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jdv.12772","volume":"29","author":"M Hertl","year":"2015","unstructured":"Hertl\u00a0M, Jedlickova\u00a0H, Karpati\u00a0S et\u00a0al (2015) Pemphigus. S2 guideline for diagnosis and treatment\u2014guided by the European dermatology forum (EDF) in cooperation with the European academy of dermatology and venereology (EADV). J\u00a0Eur Acad Dermatol Venereol 29:405\u2013415","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4610_CR18","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","volume":"142","author":"S Beissert","year":"2006","unstructured":"Beissert\u00a0S, Werfel\u00a0T, Frieling\u00a0U et\u00a0al (2006) A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 142:1447\u20131454","journal-title":"Arch Dermatol"},{"key":"4610_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1365-2249.1995.tb02268.x","volume":"101","author":"C Richter","year":"1995","unstructured":"Richter\u00a0C, Schnabel\u00a0A, Csernok\u00a0E et al (1995) Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101:2\u20137","journal-title":"Clin Exp Immunol"},{"key":"4610_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1385\/CRIAI:29:3:237","volume":"29","author":"PM Aries","year":"2005","unstructured":"Aries\u00a0PM, Hellmich\u00a0B, Gross\u00a0WL (2005) Intravenous immunoglobulin therapy in vasculitis. Clin Rev Allergy Immunol 29:237\u2013245","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"4610_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/00007611-199904000-00012","volume":"92","author":"Y Levy","year":"1999","unstructured":"Levy\u00a0Y, George\u00a0J, Fabbrizzi\u00a0F et al (1999) Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South Med\u00a0J 92:412\u2013414","journal-title":"South Med J"},{"key":"4610_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/08916930500059633","volume":"38","author":"Y Shoenfeld","year":"2005","unstructured":"Shoenfeld\u00a0Y, Katz\u00a0U (2005) IVIg therapy in autoimmunity and related disorders: our experience with a\u00a0large cohort of patients. Autoimmunity 38:123\u2013137","journal-title":"Autoimmunity"},{"key":"4610_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.humimm.2005.01.022","volume":"66","author":"E Toubi","year":"2005","unstructured":"Toubi\u00a0E, Kessel\u00a0A, Shoenfeld\u00a0Y (2005) High dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 66:395\u2013402","journal-title":"Hum. Immunol."},{"key":"4610_CR24","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/art.20195","volume":"50","author":"Y Levy","year":"2004","unstructured":"Levy\u00a0Y, Langevitz\u00a0P, Nacci\u00a0F et\u00a0al (2004) Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open label study. Arthritis Rheum 50:1005\u20131007","journal-title":"Arthritis Rheum"},{"key":"4610_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s00105-006-1113-z","volume":"57","author":"G Kukova","year":"2006","unstructured":"Kukova\u00a0G, Bruch-Gerharz\u00a0D, Gensch\u00a0K et al (2006) Skleromyx\u00f6dem. Hautarzt 57:326","journal-title":"Hautarzt"},{"key":"4610_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaad.2013.01.007","volume":"69","author":"F Rongioletti","year":"2013","unstructured":"Rongioletti\u00a0F, Merlo\u00a0G, Cinotti\u00a0E et\u00a0al (2013) Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J\u00a0Am Acad Dermatol 69:66\u201372","journal-title":"J Am Acad Dermatol"},{"key":"4610_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1365-2230.2004.01518.x","volume":"29","author":"A Karim","year":"2004","unstructured":"Karim\u00a0A, Lawlor\u00a0F, Black\u00a0MM (2004) Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin. Clin Exp Dermatol 29:317\u2013318","journal-title":"Clin Exp Dermatol"},{"key":"4610_CR28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1468-3083.2006.01951.x","volume":"21","author":"A K\u00f6rber","year":"2007","unstructured":"K\u00f6rber\u00a0A, Franckson\u00a0T, Grabbe\u00a0S et al (2007) Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin. J\u00a0Eur Acad Dermatol Venereol 21:553\u2013554","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4610_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1067\/mjd.2000.104001","volume":"43","author":"RK Lister","year":"2000","unstructured":"Lister\u00a0RK, Jolles\u00a0S, Whittaker\u00a0S et al (2000) Scleromyxedema: response to high-dose intravenous immunoglobulin. J\u00a0Am Acad Dermatol 43:403\u2013408","journal-title":"J Am Acad Dermatol"},{"key":"4610_CR30","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00105-006-1261-1","volume":"58","author":"S Topf","year":"2007","unstructured":"Topf\u00a0S, Jr. Simon\u00a0M, Schell\u00a0H et al (2007) Deutliche Besserung eines Skleromyx\u00f6dem Arndt-Gottron durch hoch dosierte intraven\u00f6se Immunglobuline. Hautarzt 58:525\u2013528","journal-title":"Hautarzt"},{"key":"4610_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/MD.0b013e3181630835","volume":"87","author":"M Blum","year":"2008","unstructured":"Blum\u00a0M, Wigley\u00a0FM, Hummers\u00a0LK (2008) Scleromyxedema. A case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine 87:10\u201320","journal-title":"Medicine"},{"key":"4610_CR32","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2340\/00015555-1299","volume":"92","author":"M Bidier","year":"2012","unstructured":"Bidier\u00a0M, Zschoche\u00a0C, Gholam\u00a0P et al (2012) Scleromyxedema: clinical follow-up after successful treatment reveals different long-term outcomes. Acta Derm Venereol 92:408\u2013409","journal-title":"Acta Derm Venereol"},{"key":"4610_CR33","volume-title":"Dermatology","author":"W H\u00f6tzenecker","year":"2018","unstructured":"H\u00f6tzenecker\u00a0W, Prins\u00a0C, French\u00a0LE (2018) Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. In: Bolognia\u00a0J, Schaffer\u00a0J, Cerroni\u00a0L (Hrsg) Dermatology, 4.\u00a0Aufl. Elsevier, Amsterdam","edition":"4"},{"key":"4610_CR34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/1346-8138.13430","volume":"43","author":"WH Chung","year":"2016","unstructured":"Chung\u00a0WH, Wang\u00a0CW, Dao\u00a0RL (2016) Severe cutaneous adverse drug reactions. J\u00a0Dermatol 43:758\u2013766","journal-title":"J Dermatol"},{"key":"4610_CR35","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"I Viard","year":"1998","unstructured":"Viard\u00a0I, Wehrli\u00a0P, Bullani\u00a0R et\u00a0al (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490\u2013493","journal-title":"Science"},{"key":"4610_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","volume":"167","author":"YC Huang","year":"2012","unstructured":"Huang\u00a0YC, Ly\u00a0YC, Chen\u00a0TC (2012) The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a\u00a0systematic review and meta-analysis. Br J Dermatol 167:424\u2013432","journal-title":"Br J Dermatol"},{"key":"4610_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ijd.12423","volume":"54","author":"SJ Barron","year":"2015","unstructured":"Barron\u00a0SJ, Del Vecchio\u00a0LT, Aronoff\u00a0SC (2015) Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a\u00a0meta-analysis with meta-regression of observational studies. Int J Dermatol 54:108\u2013115","journal-title":"Int J Dermatol"},{"key":"4610_CR38","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.intimp.2005.11.017","volume":"6","author":"S Jolles","year":"2006","unstructured":"Jolles\u00a0S, Hughes\u00a0J (2006) Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema. Int J Immunopharmacol 6:579\u2013591","journal-title":"Int. J. Immunopharmacol."},{"key":"4610_CR39","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1067\/S0190-9622(03)00785-0","volume":"49","author":"S Schanz","year":"2003","unstructured":"Schanz\u00a0S, Ulmer\u00a0A, Fierlbeck\u00a0G (2003) Intravenous immunoglobulin in livedovasculitis: a new treatment option? J\u00a0Am Acad Dermatol 49:555\u2013556","journal-title":"J Am Acad Dermatol"},{"key":"4610_CR40","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jaad.2014.05.039","volume":"71","author":"B Monshi","year":"2014","unstructured":"Monshi\u00a0B, Posch\u00a0C, Vujic\u00a0I et al (2014) Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients. J\u00a0Am Acad Dermatol 71:738\u2013744","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4610_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-018-0896-1","volume":"13","author":"H Iwata","year":"2018","unstructured":"Iwata\u00a0H, Vorobyev\u00a0A, Koga\u00a0H et al (2018) Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis 13(1):153","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4610_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","volume":"85","author":"M Amagai","year":"2017","unstructured":"Amagai\u00a0M, Ikeda\u00a0S, Hashimoto\u00a0T et al (2017) A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J\u00a0Dermatol Sci 85(2):77\u201384","journal-title":"J Dermatol Sci"},{"issue":"7","key":"4610_CR43","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/jdv.14244","volume":"31","author":"A Guarneri","year":"2017","unstructured":"Guarneri\u00a0A, Cioni\u00a0M, Rongioletti\u00a0F (2017) High-dose intravenous immunoglobulin therapy for scleromyxoedema: a\u00a0prospective open-label clinical trial using an objective score of clinical evaluation system. J\u00a0Eur Acad Dermatol Venereol 31(7):1157\u20131160","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"4610_CR44","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjd.15850","volume":"178","author":"H Song","year":"2018","unstructured":"Song\u00a0H, Lahood\u00a0N, Mostaghimi\u00a0A (2018) Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series. Br J Dermatol 178(2):363\u2013368","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"4610_CR45","first-page":"32","volume":"17","author":"K Herberger","year":"2019","unstructured":"Herberger\u00a0K, Dissemond\u00a0J, Bruggestrat\u00a0S, Sorbe\u00a0C, Augustin\u00a0M (2019) Biologics and immunoglobulins in the treatment of pyoderma gangrenosum\u2014analysis of 52 patients. J\u00a0Dtsch Dermatol Ges 17(1):32\u201341","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"4610_CR46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jamadermatol.2017.4374","volume":"154","author":"R Micieli","year":"2018","unstructured":"Micieli\u00a0R, Alavi\u00a0A (2018) Treatment for livedoid vasculopathy: a\u00a0systematic review. JAMA Dermatol 154(2):193\u2013202","journal-title":"JAMA Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04610-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-020-04610-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04610-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T02:50:29Z","timestamp":1722912629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-020-04610-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4610"],"URL":"https:\/\/doi.org\/10.1007\/s00105-020-04610-6","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"20 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E. Hadaschik hat Beraterhonorare von der Firma Biotest erhalten. A.\u00a0Enk hat Beraterhonorare der Firmen Biotest, MSD, Galderma, BMS, Janssen, Lilly\u00a0und Versabmed erhalten. D.\u00a0Zillikens erhielt Beraterhonorare\/Referentenhonorare der Firmen Fresenius, Roche, Janssen und Biotest. R.\u00a0Eming, L.E.\u00a0French, G.\u00a0Girolomoni, M.\u00a0Hertl, S.\u00a0Jolles, S.\u00a0Karpati, K.\u00a0Steinbrink, G.\u00a0Stingl und B.\u00a0Volc-Platzer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}